The maker of hard pill cannabinoid formulations said it can now fulfill the purchase order received from Australian hemp and medical cannabis group Cann Global Limited
Canntab Therapeutics Limited () (OTCQB:CTABF) (FRA:TBF1) said it has been granted an export license by Health Canada.
The maker of hard pill cannabinoid formulations said it can now fulfill the purchase order received from Australian hemp and medical cannabis group Cann Global Limited () (FRA:54A). The $406,200 order includes six stock-keeping units (SKUs) comprised of 2.5 milligrams (mg) tetrahydrocannabinol (THC), 5mg THC, 12.5mg cannabidiol (CBD), 25mg THC, and combined caplets (a hard-coated tablet in the shape of a capsule) with 5mg THC/25mg CBD and 2.5mg THC/12.5mg CBD.
The order is expected to be distributed throughout Australia to medical distributors including doctors, pharmacies, and hospitals.
WATCH: Canntab Therapeutics granted 3rd patent while also taking part in large medical cannabis study
Canntab said Cann Global is also expected to make the products it receives available to the Cannabinoid Medicine Observational Study (CMOS), which intends to collect data from 20,000 participants to assess the safety and efficacy of medicinal cannabis products for a range of refractory conditions including fibromyalgia, chronic pain syndromes, PTSD, epilepsy, and other mental health and neurological conditions.
"We are delighted to have received Health Canada's export approval to enable us to meet our Australian partners' orders in the immediate future. This is the first export order for us and we look forward to many more orders, not only from Cann Global, but from other international partners as they recognize the unique patented product offerings of Canntab,” Canntab chief executive Larry Latowsky said in a statement.
“Our order to Australia also enables us to participate in one of the largest medical cannabis studies being conducted globally, and furthermore, we have engaged with Cann Global to begin the necessary work and development to undertake clinical blood studies specifically for measuring the efficacy of our immediate and extended-release products, which we hope to conclude by the end of the summer, our third quarter," he added.
Contact the author at calum@proactiveinvestors.com
Follow him on Twitter @Cal_Proac
